Event Info
Topic:
First Nations Webinar – Optimising Kidney Health
- Date: 23/07/2024
Time:
Session 1 - 12:30 PM to 1:30 PM AEST
Session 2 - 2:30 PM to 3:30 PM AEST
Outlook
Google
Yahoo
Apple
Prof. Karen Dwyer
Speaker Director, and Professor of Nephrology & Kidney Care Services The Royal Melbourne Hospital & University of Melbourne.
Dr. Kylie Parry
Speaker General Practitioner, Wurli-Wurlinjang Health Service, Katherine
In the spirit of reconciliation AstraZeneca acknowledges Traditional Owners of Country throughout
Australia, and recognises the continuing connection to lands, waters and communities. We pay our
respects to Aboriginal and Torres Strait Islander cultures; and to Elders past, present and
emerging. We would like to acknowledge Mel Streater, artist, and descendant of the Wiradjuri Nation
who was born and lives in Birpai Country
By continuing to use this website, you consent to the terms of Webstream
Communication's Privacy Policy.
During this educational meeting AstraZeneca products may be discussed.
This meeting has been initiated, organised and funded by AstraZeneca. The content is intended for registered HealthCare Professionals for educational purposes. The company seeks no commitment from external stakeholders to take any action as a result of the invitation or related support. By joining this meeting, I agree that I will not be viewing this in general public and only with others if they are healthcare professionals that have also registered with AstraZeneca to view this event.
PHARMACOVIGILANCE (PV) ACTIVITIES : AstraZeneca continually monitor the safety profile of their products. To support this ongoing process, and to adhere with local and global regulatory obligations, we must collect all reports of potential Adverse Events (AE), special situations, and product quality complaints, in relation to a patient potentially administered an AstraZeneca product. If we identify a potential report during our communications with you, this will be shared with AstraZeneca's medical (pharmacovigilance) team. The information may be disclosed to local and overseas regulatory authorities or other third parties (such as those providing AE case processing activities, or license partners), for the purposes of meeting pharmacovigilance requirements. If you provide your contact details to us, you consent to us using those details to contact you for further information on the AE reports.
Privacy statement : Your personal information ("Information") will be collected and used by AstraZeneca Pty Ltd (ABN 54 009 682 311) ("AstraZeneca") to register you for this event, for follow-up purposes and for any other purpose described in AstraZeneca's Privacy Policy (see below for link). AstraZeneca may collect your Information from third parties such as travel agents to organise travel arrangements for an event. AstraZeneca may disclose your Information to our related entities or service providers (including IT support/service providers), some of which may be located overseas including in the US, European Union and Asia Pacific. If you do not provide your Information, AstraZeneca will not be able to register you for this event. Please refer to our Privacy Policy at http://www.astrazeneca.com.au/privacy-policy for more information about how your Information is handled and how you may seek to access or correct your Information, or submit a privacy complaint. AstraZeneca's address is 66 Talavera Road, Macquarie Park, NSW, 2113.
AstraZeneca Pty. Ltd. ABN 54 009 682 311. 66 Talavera Road, Macquarie Park, NSW 2113. www.astrazeneca.com.au. For Medical Information enquiries or to report an adverse event or product quality complaint: Telephone 1800 805 342 or via. https://contactazmedical.astrazeneca.com.
AU-19831, E-015406, E-015407, June 2024
During this educational meeting AstraZeneca products may be discussed.
This meeting has been initiated, organised and funded by AstraZeneca. The content is intended for registered HealthCare Professionals for educational purposes. The company seeks no commitment from external stakeholders to take any action as a result of the invitation or related support. By joining this meeting, I agree that I will not be viewing this in general public and only with others if they are healthcare professionals that have also registered with AstraZeneca to view this event.
PHARMACOVIGILANCE (PV) ACTIVITIES : AstraZeneca continually monitor the safety profile of their products. To support this ongoing process, and to adhere with local and global regulatory obligations, we must collect all reports of potential Adverse Events (AE), special situations, and product quality complaints, in relation to a patient potentially administered an AstraZeneca product. If we identify a potential report during our communications with you, this will be shared with AstraZeneca's medical (pharmacovigilance) team. The information may be disclosed to local and overseas regulatory authorities or other third parties (such as those providing AE case processing activities, or license partners), for the purposes of meeting pharmacovigilance requirements. If you provide your contact details to us, you consent to us using those details to contact you for further information on the AE reports.
Privacy statement : Your personal information ("Information") will be collected and used by AstraZeneca Pty Ltd (ABN 54 009 682 311) ("AstraZeneca") to register you for this event, for follow-up purposes and for any other purpose described in AstraZeneca's Privacy Policy (see below for link). AstraZeneca may collect your Information from third parties such as travel agents to organise travel arrangements for an event. AstraZeneca may disclose your Information to our related entities or service providers (including IT support/service providers), some of which may be located overseas including in the US, European Union and Asia Pacific. If you do not provide your Information, AstraZeneca will not be able to register you for this event. Please refer to our Privacy Policy at http://www.astrazeneca.com.au/privacy-policy for more information about how your Information is handled and how you may seek to access or correct your Information, or submit a privacy complaint. AstraZeneca's address is 66 Talavera Road, Macquarie Park, NSW, 2113.
AstraZeneca Pty. Ltd. ABN 54 009 682 311. 66 Talavera Road, Macquarie Park, NSW 2113. www.astrazeneca.com.au. For Medical Information enquiries or to report an adverse event or product quality complaint: Telephone 1800 805 342 or via. https://contactazmedical.astrazeneca.com.
AU-19831, E-015406, E-015407, June 2024
